Atossa Therapeutics (ATOS) Current Assets (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Current Assets of $36.7 million for Q1 2026, down 46.66% year-over-year from $68.7 million in Q1 2025, and down 19.62% quarter-over-quarter from $45.6 million in Q4 2025.
Atossa Therapeutics (ATOS) Current Assets (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Current Assets for 16 consecutive years, with $36.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 46.66% year-over-year to $36.7 million; the TTM figure through Mar 2026 stood at $36.7 million (down 46.66% YoY), while the FY2025 annual figure was $45.6 million, down 38.73% from the prior year.
- Current Assets slipped to $36.7 million in Q1 2026 per ATOS's latest filing, from $45.6 million in the prior quarter.
- Across five years, Current Assets topped out at $136.8 million in Q1 2022 and bottomed at $36.7 million in Q1 2026.
- Historically, Current Assets has averaged $88.7 million across 5 years, with a median of $87.1 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets fell 2.97% — and 2026, when it sank 46.66%.
- Atossa Therapeutics' Current Assets stood at $118.2 million in 2022, then decreased by 21.98% to $92.2 million in 2023, then decreased by 19.26% to $74.5 million in 2024, then sank by 38.73% to $45.6 million in 2025, then retreated by 19.62% to $36.7 million in 2026.
- Business Quant data shows ATOS's Current Assets at $36.7 million in Q1 2026, $45.6 million in Q4 2025, and $55.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 1.76 Bn |
| 10 | Atossa Therapeutics | 23.07 Mn | 23.07 Mn | - | 31.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.01 Mn |
| Mar 31, 2026 | 36.67 Mn |
| Dec 31, 2025 | 45.62 Mn |
| Sep 30, 2025 | 55.68 Mn |
| Jun 30, 2025 | 62.52 Mn |
| Mar 31, 2025 | 68.74 Mn |
| Dec 31, 2024 | 74.46 Mn |
| Sep 30, 2024 | 77.11 Mn |
| Jun 30, 2024 | 81.72 Mn |
| Mar 31, 2024 | 87.06 Mn |
| Dec 31, 2023 | 92.22 Mn |
| Sep 30, 2023 | 97.65 Mn |
| Jun 30, 2023 | 106.00 Mn |
| Mar 31, 2023 | 110.87 Mn |
| Dec 31, 2022 | 118.20 Mn |
| Sep 30, 2022 | 123.40 Mn |
| Jun 30, 2022 | 133.42 Mn |
| Mar 31, 2022 | 136.85 Mn |
| Dec 31, 2021 | 141.24 Mn |
| Sep 30, 2021 | 142.99 Mn |